New York, NY - Dec 24, 2019 - Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY) and Generex Biotechnology Corp (OTCQB: GNBT) through a deal announced between GNBT and US Cannabis Health, a Joint Venture partnership between KALY and Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals (USOTC: NOUV) could potentially soon introduce a cannabis drug that not only rivals GW Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex, KALY and GNBT’s cannabis drug development could reveal that GWPH’s Epidiolex infringes on GNBT patents.
"I believe the underlying value of Kali-Extracts cannabis biotechnology properties are as of yet unrecognized by the market," said Frederick Ferri, CEO of Kali-Extracts. "Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals [GW Pharmaceuticals, plc (GWPH)]. As just one example of what our cannabis biotechnology can lead to, I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market. For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well. I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology. I hope the COPD example herein begins to give a glimpse of that yet to be realized value. Finally, I think the developing partnership between KALY and its other US Cannabis Health partners with Generex can put KALY, its other US Cannabis Health partners and Generex on top of their respective markets." (source - yahoo.com)
KALY and GNBT could impact Motley Fool’s 2019 prediction for GWPH. See Motley Fool’s prediction #4 of 7 for cannabis stocks in 2019:
4. First U.S. plant-based cannabinoid drug is a big hit, Big Pharma execs injure themselves after slapping foreheads in regret
Despite some nattering negativism by skeptics, GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, the first plant-based cannabinoid drug approved in the U.S., becomes a smashing commercial success. Even pessimistic analysts project that Epidiolex likely will become a blockbuster within a few years.
As Epidiolex sales steadily increase, several renowned Big Pharma executives are forced to receive medical care for injuries received from slapping themselves on the foreheads in regret. These slaps stem from the executives reading the histories of their companies marketing cannabis-based drugs in the early 20th century. (Source: Motley Fool)
Keep an eye on KALY and GNBT. Both are showing characteristics of entry level prices you might regret missing.
Learn more about Kali, Inc. at www.kali-extracts.com.
Learn more about Generex at www.generex.com.
NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.